BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
REDWOOD CITY, Calif., Feb. 22, 2017 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that the Company will be participating in two upcoming investor conferences.
Avinger’s management is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2017 at 11:20am ET.
Avinger’s management is also scheduled to present at the Oppenheimer 27th Annual Healthcare Conference in New York, NY on Wednesday, March 22, 2017 at 10:20am ET.
Interested parties can access the live audio webcast with accompanying slides for both of these presentations on the Events section of Avinger’s website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the legs and feet. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.
Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
